Astellas sells its dipeptidyl peptidase-4 (DPP-4) patent estate and royalty stream to Royalty Pharma for $609 million in cash

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Royalty Pharma

U.S. / Financial

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced